Dr Reddy's Generic Lenacapavir Gets FDA Tentative Approval

Dr. Reddy’s Laboratories has received tentative approval from the US Food and Drug Administration (FDA) for its generic version of lenacapavir, a long-acting injectable medicine used to prevent HIV infection. The regulatory milestone could accelerate access to the treatment across 120 low- and middle-income countries covered by licensing agreements with its developer, Gilead Sciences.

Announced on 2 November 2026, the approval makes Dr Reddy’s the first of six licensed generic manufacturers to secure tentative FDA approval for the medicine. The development is expected to support regulatory reviews and procurement processes in eligible markets, bringing a lower-cost version of the treatment closer to commercial distribution.

The generic injection is expected to cost approximately $40 per person annually, compared with around $28,000 for Gilead’s branded Yeztugo in the United States, according to global health agencies.

Initial supplies are expected to reach selected low-income countries before the end of 2026, with wider availability across eligible markets planned for 2027.

Dr Reddy’s Generic Lenacapavir Receives Tentative FDA Approval

The FDA’s tentative approval confirms that Dr Reddy’s generic formulation has met the agency’s requirements for safety, efficacy and quality.

However, the designation does not permit the medicine to be marketed commercially in the United States while relevant patent or exclusivity restrictions remain in place.

Its significance lies in the role of the FDA assessment in supporting regulatory reliance mechanisms. Certain national regulators and international procurement organisations can use the assessment when evaluating the product for approval and purchasing decisions.

Jessica Burry, a technical officer at Unitaid, said the regulatory milestone could help some countries accelerate their approval processes by relying on the FDA’s assessment. It could also support faster procurement.

Dr Reddy’s is working with Unitaid, the Clinton Health Access Initiative (CHAI) and the Wits Reproductive Health and HIV Institute (Wits RHI) to accelerate the development and availability of the generic medicine.

How Lenacapavir Works as a Twice-Yearly HIV Prevention Drug

Lenacapavir is an antiviral medicine developed by Gilead Sciences and marketed for HIV prevention under the brand name Yeztugo.

Unlike conventional oral pre-exposure prophylaxis (PrEP), which generally requires daily medication, lenacapavir is administered through an injection twice a year.

The treatment is intended to reduce the risk of sexually acquired HIV-1 infection. Clinical trials reported near-complete protection against HIV acquisition among participants receiving the injection, making it an important development in long-acting HIV prevention.

The twice-yearly administration schedule could offer an alternative for people who face difficulties maintaining daily medication routines.

For healthcare systems and public health programmes, the availability of a long-acting prevention option could also influence how HIV prevention services are delivered, provided that affordable supplies, testing and appropriate clinical services are available.

Generic Lenacapavir Targets $40 Annual Cost per Person

Affordability is central to the planned rollout of Dr Reddy’s generic lenacapavir.

Under the pricing arrangement supported by Unitaid, CHAI and Wits RHI, the medicine is expected to be available at approximately $40 per person annually across the 120 low- and middle-income countries covered by Gilead’s voluntary licensing agreements.

This compares with approximately $28,000 for branded Yeztugo in the US market.

The substantial difference reflects the focus on developing a lower-cost supply model for countries where the financial burden of HIV prevention programmes can restrict access to newer medicines.

The pricing arrangement was established through a partnership announced in September 2025. It combines financial, technical and regulatory support to accelerate generic development and market entry.

The collaboration also illustrates how pharmaceutical manufacturers and global health organisations can work together to shorten the time between the introduction of an innovative medicine and the availability of more affordable generic alternatives.

Gilead Licensing Supports Generic Lenacapavir Manufacturing

The development builds on a voluntary licensing agreement between Dr Reddy’s and Gilead Sciences.

Under the agreement announced in October 2024, Dr Reddy’s received a royalty-free, non-exclusive licence to manufacture and commercialise lenacapavir in India and other eligible countries.

Gilead subsequently licensed the medicine to six generic manufacturers, including Dr Reddy’s, Hetero, Emcure, Eva Pharma, Ferozsons Laboratories and Mylan, a subsidiary of Viatris.

The arrangements are intended to establish multiple sources of generic production and support broader access across 120 countries covered by the licensing framework.

Dr Reddy’s has become the first of these six manufacturers to receive tentative FDA approval for its generic version, potentially giving it an early regulatory milestone in the planned international rollout.

Separately, Hetero is working with the Gates Foundation on generic lenacapavir, highlighting the participation of multiple Indian pharmaceutical manufacturers in expanding access to the medicine.

Zambia Could Receive Initial Generic Lenacapavir Supplies

Initial supplies of Dr Reddy’s generic lenacapavir are expected to reach a limited number of low-income countries before the end of 2026.

Unitaid identified Zambia as a potential early recipient, while broader distribution across eligible markets is expected during 2027.

The pace of rollout will depend on country-level regulatory processes, procurement arrangements, manufacturing capacity and the availability of funding for public health programmes.

The FDA milestone could help reduce regulatory delays in countries that rely on assessments conducted by established international regulators. However, tentative approval does not automatically constitute marketing authorisation in every participating country.

The wider programme is intended to make long-acting HIV prevention more accessible in regions where the disease continues to represent a significant public health challenge.

Indian Drugmakers Expand Role in Global HIV Prevention

The development highlights the expanding role of Indian pharmaceutical companies in the global supply chain for complex generic medicines.

Dr Reddy’s participation combines generic drug development and manufacturing capabilities with international licensing arrangements and technical support from global health organisations.

The regulatory achievement also demonstrates the potential for collaboration between pharmaceutical innovators, generic manufacturers and procurement agencies to accelerate access to newer treatments.

For the generic pharmaceutical industry, the next important milestones will be the commencement of commercial supplies, country-level approvals and the ability to maintain consistent production at the targeted price.

With initial deliveries expected before the end of 2026 and broader availability planned for 2027, Dr Reddy’s tentative FDA approval represents an important step towards expanding access to long-acting HIV prevention in eligible markets.

Follow B2B Market Signal on social media for the latest business news, industry developments, market intelligence and analysis. Connect with us on LinkedIn and follow us on Instagram at @b2bmarketsignal for regular updates